Addex Therapeutics Establishes Scientific Advisory Board
19 May 2020 - 3:00PM
World-leading experts will support
our strategic decision-making processes as we continue advancing
our pipeline of allosteric modulators
Geneva, Switzerland, May 19,
2020 - Addex Therapeutics Ltd (SIX
and Nasdaq: ADXN), a clinical-stage pharmaceutical company
pioneering allosteric modulation-based drug discovery and
development, announced today that it has established a Scientific
Advisory Board (SAB) led by Darryle Schoepp, PhD, as Chairman (see
Press Release) and including fellow world-leading neuroscientists
and drug discovery & development experts, Prof. Mark F. Bear,
PhD, Peter R. Bernstein, PhD, and Prof. Bernard Bettler, PhD. The
SAB will provide valuable insight to help steer future application
of Addex proprietary allosteric modulation technology platform and
unique pipeline in neurological and other diseases.
‘‘The formation of our SAB with these
world-leading experts is an important step for us as we not only
execute on our registration program with dipraglurant in PD-LID,
but look to our preclinical pipeline as it progresses towards the
clinic,” said Tim Dyer, Chief Executive Officer of Addex. ‘‘Their
expertise will be invaluable as we execute on our strategy to build
a leading neuroscience company based on allosteric modulation.”
Dr. Mark Bear is a Picower Professor of
Neuroscience in The Picower Institute for Learning and Memory and
the Department of Brain and Cognitive Sciences, Massachusetts
Institute of Technology. He was an Investigator of the Howard
Hughes Medical Institute for 22 years. Dr. Bear’s laboratory has
substantially advanced knowledge of how cerebral cortex is modified
by experience. He made fundamental discoveries on
bidirectional synaptic plasticity, metaplasticity, the molecular
basis of amblyopia (a cause of visual disability in children), and
the pathophysiology of fragile X syndrome (the most common
inherited cause of intellectual disability and autism). He has
been at the forefront of the efforts to translate knowledge of
autism pathophysiology into new treatments.
During his distinguished career at AstraZeneca,
Dr. Peter Bernstein helped develop multiple treatments, acting via
different mechansims of action, targeting several diseases. More
than 10 of these compounds entered into clinical development. Early
in his career he co-invented and helped develop Accolate®
(Zafirlukast), the first leukotriene antagonist to be approved in
the US. Dr. Bernstein then went on to work on or lead
teams targeting: neurokinin antagonists, β-estrogen agonists,
γ-secretase inhibitors, H3 antagonists, 5-HT1B antagonists and
dual NET/DAT reuptake inhibitors. Dr. Bernstein is an author on
over 200 scientific papers, presentations, and patents. He is a
member of the ACS MEDI Hall of Fame and is a fellow of the American
Chemical Society.
Dr. Bernard Bettler is a Professor in the
Department of Biomedicine at Basel University, Switzerland. His
laboratory is exploring GPCR complexes and how the composition of
these complexes influences fundamental processes, such as neuronal
excitability and network activity, with the ultimate goal of
identifying novel drug targets for the treatment of neurological
and psychiatric diseases. He was previously a project manager at
Novartis working on GABAB receptors, a receptor he cloned and
helped characterise. While at Novartis his team identified the
first allosteric modulators at GABAB receptors. Dr. Bettler is the
2017 recipient of the Peter Speiser Award from the ETH Zurich for
outstanding achievments in the pharmaceutical sciences.
About Addex
TherapeuticsAddex Therapeutics is a clinical-stage
pharmaceutical company focused on the development and
commercialization of an emerging class of novel orally available
small molecule drugs known as allosteric modulators for
neurological disorders. Allosteric modulators offer several
potential advantages over conventional non-allosteric molecules and
may offer an improved therapeutic approach to conventional
"orthosteric" small molecule or biological drugs. Addex's
allosteric modulator drug discovery platform targets receptors and
other proteins that are recognized as essential for therapeutic
intervention. Addex's lead drug candidate, dipraglurant (mGlu5
negative allosteric modulator or NAM), is scheduled to enter a
pivotal registration clinical trial for Parkinson’s disease
levodopa induced dyskinesia (PD-LID). In parallel, dipraglurant's
therapeutic use in dystonia is being investigated in preclinical
models. Addex's second clinical program, ADX71149 (mGlu2 positive
allosteric modulator or PAM) is being developed in collaboration
with Janssen Pharmaceuticals, Inc for the treatment of epilepsy. In
addition, Addex’s GABAB PAM program has been licensed to
Indivior PLC for the treatment of addiction. Preclinical programs
include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for
mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease
and mGlu3 PAM for neurodegenerative
disorders.
Press Contacts:
Tim DyerChief Executive OfficerTelephone: +41 22 884 15
55Email: PR@addextherapeutics.com |
Mike SinclairPartner, Halsin Partners+44 (0)20 7318
2955msinclair@halsin.com |
Forward Looking Statements
Certain statements made in this announcement are
forward-looking statements including with respect to the creation
of a trading market for ADSs representing the Company's shares
in the United States. These forward-looking statements are not
historical facts but rather are based on the Company's current
expectations, estimates, and projections about its industry; its
beliefs; and assumptions. Words such as 'anticipates,' 'expects,'
'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar
expressions are intended to identify forward-looking statements.
These statements are not guarantees of future performance and are
subject to known and unknown risks, uncertainties, and other
factors, some of which are beyond the Company's control, are
difficult to predict, and could cause actual results to differ
materially from those expressed or forecasted in the
forward-looking statements. The Company cautions securityholders
and prospective securityholders not to place undue reliance on
these forward-looking statements, which reflect the view of the
Company only as of the date of this announcement. The
forward-looking statements made in this announcement relate only to
events as of the date on which the statements are made. The Company
will not undertake any obligation to release publicly any revisions
or updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of
this announcement except as required by law or by any appropriate
regulatory authority.
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Apr 2024 to May 2024
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From May 2023 to May 2024